Table 2.
The relationships between Ki-67/MIB-1 expression and clinicopathologic parameters
| Clinicopathologic parameters | Studies (n) | Test group
|
Control group
|
Heterogeneity
|
Meta-analysis model | OR (95% CI) | P-value | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Events | Total | Events | Total | I2, % | P-value | |||||
| Age (45 years) | 10 | 124 | 303 | 91 | 239 | 0.00 | 0.806 | Fixed-effect analysis | 1.71 (1.14–2.57) | 0.01 |
| Tumor size (4 cm) | 5 | 35 | 165 | 76 | 730 | 2.00 | 0.395 | Fixed-effect analysis | 1.86 (1.17–2.96) | 0.008 |
| Lymph node metastasis | 15 | 233 | 345 | 226 | 509 | 50.20 | 0.014 | Random-effect analysis | 2.49 (1.42–4.39) | 0.002 |
| Metastasis status | 7 | 75 | 133 | 121 | 920 | 59.80 | 0.021 | Random-effect analysis | 6.96 (2.46–19.69) | <0.001 |
| TNM stage | 7 | 113 | 146 | 103 | 247 | 0.00 | 0.96 | Fixed-effect analysis | 6.56 (3.80–11.34) | <0.001 |
| Extrathyroid extension | 4 | 64 | 225 | 79 | 413 | 31.30 | 0.224 | Fixed-effect analysis | 1.91 (1.27–2.87) | 0.002 |
Abbreviations: CI, confidence interval; OR, odds ratio; TNM, tumor node metastasis.